• XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis

    • August 2, 2018
    • Posted By : admin
    • 0 Comment

    Pfizer Inc. PFE, +0.85% announced today that the European Commission (EC) has approved XELJANZ [®] (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. [1] XELJANZ is the first and only oral therapy and Janus kinase (JAK) inhibitor to be approved for this patient population.

    In approving XELJANZ for UC, the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has, as part of its assessment, determined XELJANZ to be of significant clinical benefit for patients with UC in comparison with existing therapies.

    “Ulcerative colitis is a chronic disease that can develop at any age, be difficult to manage and affect multiple aspects of daily life,” said Angela Lukin, regional president, Inflammation and Immunology, Pfizer. “The EC approval of XELJANZ provides an additional treatment option that can help improve the care of adults in Europe living with this debilitating inflammatory bowel disease.”

    XELJANZ is now approved for three indications in the EU. In 2017, XELJANZ, in combination with methotrexate (MTX), was first approved by the EC for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs), and as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. [2] In June 2018, XELJANZ, in combination with MTX, was approved by the EC for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. [2]

    “Until now, people living with moderately to severely active ulcerative colitis have not had an oral treatment available that can both induce and maintain steroid-free remission,” said Silvio Danese, head of IBD Center, Department of Gastroenterology Humanitas Research Hospital, Milan, Italy, President of the European Crohn’s and Colitis Organisation (ECCO) Governing Board. “This approval of XELJANZ, the first JAK inhibitor to be approved for this condition, offers the ulcerative colitis community an additional treatment option.”


You Might Also Like

No comments found



error: Content is protected !!